CPT Code Anticipated For AMD Combination Therapy Using Lasers, QLT Says
This article was originally published in The Gray Sheet
Executive Summary
A combination drug/device therapy for "wet" age-related macular degeneration (AMD) will likely have a current procedural terminology (CPT) payment code in effect by Jan. 1. The treatment uses QLT PhotoTherapeutics' injectable drug Visudyne (verteporfin) activated by lasers manufactured by Coherent Medical (Opal Photoactivator) and Zeiss Humphrey Systems (Visulas 690).
You may also be interested in...
QLT PhotoTherapeutics
FDA approval of Visudyne (verteporfin for injection) to treat "wet" age-related macular degeneration in conjunction with lasers made by Coherent and Zeiss Humphrey Systems to activate the photodynamic therapy is announced April 13. Independent marketing of Coherent's Opal Photoactivator and Zeiss' Visulas 690 PDT lasers, which have only slightly different features, commenced immediately following approval. The Opal is priced in the $40,000-50,000 range and the Visulas is priced at $37,900-44,900, depending on configuration with or without a slitlamp
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.